Medacta GroupFRA:6MD +1.42%91 OCF Yield % is 5.36 as of Jun. 25, 2026, which is 72% above its 10-year median of 3.11. GuruFocus rates FRA:6MD with a GF Score™ of 91/100 and a GF Value™ of €178.79 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Medacta Group ranks better than 67.25% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Medacta Group's OCF Yield % or its related term are showing as below:
FRA:6MD'
s OCF Yield % Range Over the Past 10 Years
Min: 1.98 Med: 3.11 Max: 5.42
Current: 5.36
During the past 11 years, the highest OCF Yield % of Medacta Group was 5.42%. The lowest was 1.98%. And the median was 3.11%.
FRA:6MD's OCF Yield % is ranked better than 67.25% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 1.76
vs FRA:6MD: 5.36
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Medacta Group OCF Yield % Related Terms
Medacta Group OCF Yield % Historical Data
* Premium members only.
The historical data trend for Medacta Group's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medacta Group's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Medacta Group's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medacta Group (FRA:6MD) has a OCF Yield % of 5.36 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Medacta Group and its competitors. This is 72% above median its historical median of 3.11. Over the past decade, Medacta Group's OCF Yield % has ranged from 1.98 to 5.42. According to the industry distribution chart, Medacta Group ranks #279 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 32.7%.
Is Medacta Group's OCF Yield % too high?
Medacta Group's current OCF Yield % of 5.36 is 72% above median its 10-year median of 3.11. Over the past 10 years, this metric has ranged from a low of 1.98 to a high of 5.42. The Medical Devices & Instruments industry median OCF Yield % is 1.76. Medacta Group's value of 5.36 is 204.5% above this industry median. Based on the distribution chart, Medacta Group ranks #279 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medacta Group has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's OCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #279 out of 852 companies for OCF Yield %. This puts Medacta Group in the upper half of its industry. The industry median OCF Yield % is 1.76. Medacta Group's value of 5.36 is 204.5% above this benchmark. Historically, Medacta Group's own OCF Yield % has ranged from 1.98 to 5.42 over the past decade. While the company's 10-year median is 3.11 vs. the industry median of 1.76, Medacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.76, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current OCF Yield % of 5.36 is 204.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Medacta Group and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current OCF Yield % is 5.36, which is 72% above median its own 10-year median of 3.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (FRA:6MD) is currently considered Modestly Undervalued. The stock's GF Value™ is €178.79, compared to a current price of €143.00 — trading 20% below its estimated fair value. The current OCF Yield % is 5.36, which is 72% above median its 10-year median of 3.11 and 204.5% above the Medical Devices & Instruments industry median of 1.76. Medacta Group's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Medacta Group (FRA:6MD), the current OCF Yield % is 5.36 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (FRA:6MD) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of €143.00 is trading 20% below its estimated GF Value™ of €178.79.
GuruFocus considers Medacta Group to be Modestly Undervalued.
Key valuation signals for FRA:6MD:
OCF Yield %: 5.36 (72% above median its 10-year median of 3.11)
GF Value™: €178.79 vs. price of €143.00 (20% below fair value)
Industry Position: 204.5% above the Medical Devices & Instruments median (#279 of 852)
No single metric tells the full story. See the FRA:6MD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
91GF Score
Get the complete analysis for FRA:6MD
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6MD has been successfully added to your 
